Physician profile
John Gerig
NPI 1477550440
$2,835.12
in general payments reported to CMS, 2019-2025
9 companies · $53.45 in 2025
The $53.45 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $1,663 · 2021: $179 · 2022: $177 · 2023: $116 · 2025: $53.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.31 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,122.99 | 2019-2022 | |
| Akebia Therapeutics INC | $146.73 | 2019-2020 | |
| Nxstage Medical, INC. | $121.71 | 2022 | |
| Travere Therapeutics, INC. | $116.31 | 2023 | |
| Alexion Pharmaceuticals, INC. | $115.90 | 2019 | |
| Mallinckrodt Enterprises LLC | $93.24 | 2019 | |
| Genentech, INC. | $53.45 | 2025 | |
| Amgen INC. | $51.35 | 2019 | |
| Fresenius USA Marketing, INC. | $13.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gerig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.